Edwards Lifesciences is headquartered in Irvine, California, and has operations in more than 25 countries. It is a global leader in the science of heart valves and hemodynamic monitoring. The company designs manufacture and markets products and technologies to treat advanced cardiovascular disease.
Edwards Lifesciences products are used by clinicians to treat patients suffering from structural heart disease and critically ill patients in intensive care. The company’s products are used in more than 100 countries and include transcatheter heart valves, transcatheter repair products, heart valve repair, and replacement technologies, and hemodynamic monitoring systems.
Our patient-focused innovative technologies such as Transcatheter heart valves, Critical care technologies, Surgical valve technologies, and Transcatheter mitral and tricuspid therapies are designed to help improve patient outcomes and provide treatment options for a range of heart conditions.
Edwards Lifesciences is a leading company in the field, known for its commitment to innovation and its focus on delivering advanced cardiovascular technologies to improve patient care. The company’s products are used globally by healthcare professionals to treat patients with structural heart disease and in critical care settings.
Transcatheter Aortic Valve Implantation (TAVI/TAVR)
Transcatheter Aortic Valve Implantation (TAVI), also known as Transcatheter Aortic Valve Replacement (TAVR), is a minimally invasive procedure used to treat aortic stenosis, a condition in which the aortic valve of the heart narrows and restricts blood flow to the body. During the procedure, a new valve is implanted over the existing, damaged valve, without open-heart surgery.
The TAVI procedure involves making a small incision in the groin or chest and threading a thin, flexible catheter through the artery to the heart. A balloon is then used to expand the new valve in place over the existing valve, securing it with small metal anchors. The procedure usually takes a few hours and is performed under local anesthesia.
TAVI is typically recommended for patients who are at high or intermediate risk for traditional open-heart surgery, or who are not good candidates for surgery due to other medical conditions. The procedure offers several benefits over conventional surgery, including faster recovery times, shorter hospital stays, and reduced risk of complications.
TAVI offers several advantages over traditional open-heart surgery, including:
- Minimally invasive: TAVI is a minimally invasive procedure, which means that it is less invasive than traditional open-heart surgery. This results in less pain and scarring, shorter recovery times, and reduced risk of complications.
- Quicker recovery: TAVI allows for a quicker recovery time than traditional open-heart surgery. Most patients can leave the hospital within a few days after the procedure and can resume normal activities within a few weeks.
- Reduced risk of complications: TAVI has been shown to have a lower risk of complications, such as bleeding and infection, compared to traditional open-heart surgery.
- Suitable for high-risk patients: TAVI is a good option for patients who are at high or intermediate risk for traditional open-heart surgery, or who are not good candidates for surgery due to other medical conditions.
Improved quality of life: TAVI has been shown to improve symptoms and quality of life in patients with severe aortic stenosis, allowing them to live more active and fulfilling lives.
Edwards Lifesciences Medical Devices
1 – SAPIEN 3
SAPIEN 3 is a transcatheter aortic valve replacement (TAVR) device manufactured by Edwards Lifesciences. It is a minimally invasive procedure used to replace a diseased aortic valve in patients with severe aortic stenosis. The device is made of a self-expanding nitinol frame and a bovine pericardial tissue valve.
It is designed to be implanted through a catheter inserted through a small incision in the groin or chest. The device is designed to reduce the risk of stroke and improve the quality of life for patients with severe aortic stenosis.
2 – SAPIEN 3 Ultra
The SAPIEN 3 Ultra is a type of transcatheter aortic valve replacement (TAVR) device. It is used to replace a narrowed or malfunctioning aortic valve in the heart without the need for open-heart surgery. The SAPIEN 3 Ultra is a third-generation TAVR device and it is considered to be the most advanced TAVR device on the market.
It is designed to provide improved outcomes for patients who are at high or extreme risk for open-heart surgery, including those with severe aortic stenosis. The device is inserted through a small incision in the leg or chest and guided to the heart where it is deployed to replace the malfunctioning valve.
The SAPIEN 3 Ultra has been shown to be as effective as open-heart surgery in clinical studies and has a lower risk of complications.
3 – SAPIEN XT
The SAPIEN XT Transcatheter Heart Valve is a device used to replace a diseased or damaged aortic valve in the heart. It is a minimally invasive procedure that is used to treat aortic stenosis, a condition in which the aortic valve does not open properly, resulting in reduced blood flow to the rest of the body.
The SAPIEN XT Transcatheter Heart Valve is inserted through a catheter, which is inserted through a small incision in the groin or chest. The device is then guided through the blood vessels to the heart, where it is positioned and deployed.
The device is made of a metal frame and a fabric-covered balloon, which expands to replace the damaged valve. The SAPIEN XT Transcatheter Heart Valve is designed to provide improved hemodynamic performance and improved patient outcomes.